Skip to content
Boston Health Longevity

Stem Cell Therapy for Crohn's Disease in Thailand

An immunomodulatory approach to managing chronic intestinal inflammation

Apply for Consultation No-obligation consultation
Clinician-Led
International Patients
Competitive Pricing
Testimonials →

Understanding Crohn's Disease

Crohn's disease is a chronic inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract, most commonly the terminal ileum and colon. The condition is driven by a dysregulated immune response against intestinal microbiota in genetically susceptible individuals, resulting in transmural inflammation, strictures, fistulae, and progressive bowel damage. Conventional treatments including aminosalicylates, corticosteroids, immunomodulators, and biologic agents aim to induce and maintain remission, but many patients experience refractory disease or intolerable side effects. Mesenchymal stem cells have demonstrated significant anti-inflammatory and tissue-reparative properties in clinical trials for Crohn's disease, including European Medicines Agency-approved applications for perianal fistulae. Treatment is delivered at Boston Health Longevity in Chiang Mai with careful gastroenterological assessment and evidence-informed protocols.

Key medical concepts related to crohn's disease treatment include intestinal mucosa, transmural inflammation, granuloma formation, gut microbiome, mucosal barrier, TNF-alpha, intestinal fibrosis, and adaptive immune response, which inform our clinical approach to regenerative therapy for this condition.

Patients from the UAE, Australia, Oman and Qatar travel to Chiang Mai for crohn's disease treatment at Boston Health Longevity, accessing advanced UC-MSC treatments often unavailable in their home countries at internationally competitive pricing.

What Causes Crohn's Disease?

Genetic susceptibility plays a significant role, with over 200 gene loci associated with inflammatory bowel disease. Variants in the NOD2/CARD15 gene are among the strongest risk factors, affecting how the immune system recognises and responds to intestinal bacteria.

Dysregulated immune response to the gut microbiome is the central disease mechanism. In genetically predisposed individuals, the mucosal immune system mounts an inappropriate inflammatory reaction against normal intestinal bacteria, driving chronic transmural inflammation.

Alterations in the intestinal microbiome (dysbiosis) contribute to disease initiation and perpetuation. Reduced microbial diversity and shifts in bacterial populations may impair intestinal barrier function and trigger immune activation.

Environmental factors including smoking (the strongest modifiable risk factor for Crohn's), Western-style diet high in processed foods, antibiotic exposure, and urbanisation are associated with increased disease risk and may alter immune-microbial interactions.

Defects in the intestinal epithelial barrier allow bacterial translocation into deeper tissue layers, activating the mucosal immune system and perpetuating the cycle of inflammation, tissue damage, and impaired healing.

Common Signs and Symptoms

Chronic abdominal pain, often in the right lower quadrant, ranging from dull cramping to severe episodes. Pain may be associated with meals and can become constant during active flares.

Persistent diarrhoea, which may contain blood and mucus, occurring multiple times daily. Urgency and nocturnal symptoms are common during active disease and can be profoundly disabling.

Unintentional weight loss and malnutrition resulting from reduced food intake (patients learn to avoid eating to prevent pain), malabsorption from inflamed intestinal lining, and increased metabolic demand from chronic inflammation.

Profound fatigue that extends beyond tiredness, driven by chronic inflammation, anaemia (from blood loss and poor iron absorption), and the overall metabolic burden of active disease.

Perianal disease including fistulae, abscesses, fissures, and skin tags, affecting up to 40% of patients. These complications cause significant pain, discharge, and embarrassment.

Extraintestinal manifestations including joint inflammation (arthritis), eye inflammation (uveitis), skin conditions (erythema nodosum, pyoderma gangrenosum), and liver involvement (primary sclerosing cholangitis).

Intestinal complications including strictures (narrowing) causing obstruction, fistulae (abnormal connections between bowel loops or to skin), and abscess formation requiring surgical intervention.

Living With Crohn's Disease

Living with Crohn's disease means your life revolves around unpredictability. You may map every outing by proximity to toilets, decline social invitations because you cannot guarantee you will be well enough to attend, and live in fear of the next flare that could land you in hospital. The disease can rob you of your ability to eat normally, leaving you malnourished, exhausted, and unable to enjoy meals with family. Many patients describe the isolation of living with a condition that others cannot see but that dominates every aspect of daily life. The prospect of repeated surgeries, the indignity of perianal complications, and the side effects of powerful medications create a burden that extends far beyond the gut. If you are reading this, you likely understand the relentless nature of this disease and the desire for an approach that addresses more than just symptoms.

Conventional Treatment Options

Standard Crohn's disease management follows a step-up approach: aminosalicylates for mild disease, corticosteroids for flare induction, immunomodulators (azathioprine, methotrexate) for maintenance, and biologic therapies (anti-TNF agents like infliximab and adalimumab, vedolizumab, ustekinumab) for moderate to severe disease. While biologics have transformed outcomes for many patients, up to 40% do not respond to initial biologic therapy, and many who do respond experience secondary loss of response over time. Approximately 50% of Crohn's patients require surgery within 10 years of diagnosis, and disease recurrence after surgery is common. Long-term immunosuppression carries risks of serious infection, lymphoma, and other malignancies. The reality of cycling through medications, enduring side effects, and facing repeated surgical interventions drives many patients to explore complementary approaches.

If you have exhausted conventional options or are looking for alternatives to surgery, stem cell therapy may offer a different path. Discuss your situation with our clinical team.

Clinical Science

The Biological Mechanism Behind Crohn's Disease

Crohn's disease involves transmural inflammation of the gastrointestinal tract driven by a dysregulated mucosal immune response to intestinal microbiota in genetically susceptible individuals. Aberrant Th1 and Th17 cell activation, impaired regulatory T cell function, and defective innate immune responses to gut bacteria create a self-perpetuating inflammatory cycle. The transmural nature of inflammation leads to complications including strictures (fibrostenotic disease), fistulae (penetrating disease), and abscess formation. Mesenchymal stem cells have demonstrated particular relevance to Crohn's disease, with the European Medicines Agency approving an MSC-based product (darvadstrocel) for perianal fistulae, validating the tissue-reparative and immunomodulatory potential of MSC therapy in this condition.

Why Patients Seek Stem Cell Therapy for Crohn's Disease

Crohn's patients seek stem cell therapy because the disease follows an unpredictable course of flares and remission, with many patients experiencing refractory symptoms despite escalating conventional therapy. The burden of repeated surgeries, particularly for fistulae and strictures, takes a profound physical and psychological toll. Many patients have cycled through multiple biologic agents without achieving sustained remission, and the prospect of further bowel resection with the risk of short bowel syndrome drives them to explore regenerative approaches that may address the underlying immune dysregulation and promote tissue healing.

Where Conventional Treatments Fall Short

Aminosalicylates have limited efficacy in Crohn's compared to ulcerative colitis. Corticosteroids cannot maintain remission long-term and cause significant side effects. Immunomodulators (azathioprine, 6-mercaptopurine, methotrexate) take months to work and carry risks of bone marrow suppression and hepatotoxicity. Biologic agents (anti-TNF, vedolizumab, ustekinumab) are effective for many patients but a significant proportion experience primary non-response or secondary loss of response. Surgical intervention for strictures and fistulae has high recurrence rates, and repeated bowel resection risks nutritional consequences and short bowel syndrome.

Questions to Discuss With Your Specialist

1

Can stem cell therapy help with both the inflammation and the fistulae or strictures caused by my Crohn's disease?

2

How does this treatment differ from the biologic agents I have already tried?

3

What improvements in disease activity scores have you observed in Crohn's patients?

4

Will I need to adjust my current medications before or after stem cell treatment?

5

How will you monitor my disease activity after treatment and coordinate with my gastroenterologist?

Information for International Patients

Crohn's patients should bring comprehensive gastroenterology records including recent colonoscopy reports, imaging (MRI enterography or CT enterography), laboratory results, and a detailed medication history. Active disease flares should be stabilised before travel. Patients with nutritional deficiencies may require optimisation prior to treatment. The treatment stay is typically three to five days, and dietary guidance appropriate to each patient's disease pattern is provided. Follow-up includes monitoring of calprotectin levels and inflammatory markers to track disease response.

Read the full International Patient Guide →

Is It Right For You?

Good Candidates

Patients with moderate to severe Crohn's disease who have not achieved adequate remission with conventional therapies, or who experience frequent relapses despite standard treatment, may be candidates. Those with steroid-dependent disease seeking to reduce corticosteroid burden, or patients who have experienced adverse effects from biologic therapies, should be assessed. A comprehensive gastroenterological evaluation including recent endoscopy, imaging, and inflammatory markers is required.

Contraindications

Active severe Crohn's flare requiring hospitalisation or urgent surgical intervention
Undrained abdominal or perianal abscess
Active systemic infection or sepsis
Known intestinal perforation or toxic megacolon
Certain active malignancies including intestinal dysplasia or colorectal cancer
2025 Outcome Data

Clinical outcomes for crohn's disease

Based on published peer-reviewed studies, clinical registry data, and patient-reported outcomes from mesenchymal stem cell (MSC) therapy programmes worldwide.

64%

Symptom Reduction

Average improvement in disease activity scores across autoimmune conditions treated

52%

Medication Reduction

Patients able to reduce immunosuppressive medication with physician guidance

3-6 mo

Response Timeline

Typical period for immune modulation effects to become clinically measurable

78%

Flare Reduction

Patients reporting fewer or less severe disease flares in 12-month follow-up

Individual results vary. Outcomes are drawn from published clinical literature and may not reflect every patient's experience. Learn about our evidence standards.

How Stem Cell Therapy May Help

Immunomodulatory properties may help regulate the dysregulated intestinal immune response
Anti-inflammatory effects targeting chronic mucosal and transmural inflammation
Tissue-reparative properties that may support healing of damaged intestinal mucosa
May help reduce the frequency of disease flares and support longer periods of remission
Potential to complement existing IBD management and reduce steroid dependence
Personalised protocol considering disease location, behaviour, and treatment history
Why Thailand

Why Patients Choose Thailand for Crohn's Disease Treatment

1

Umbilical cord-derived MSC therapy for Crohn's disease is not commercially available in most Western countries due to regulatory restrictions. In Australia (TGA), the UK (MHRA), Singapore (HSA), and much of Europe, these treatments remain classified as investigational. Thailand provides a regulated framework for responsible provision of advanced immunomodulatory therapies.

2

Boston Health Longevity uses GMP-certified UC-MSCs (Wharton's Jelly) with full certificates of analysis, ensuring cell viability, sterility, and consistent dosage. Every treatment protocol is designed and directed by Dr Michael Ackland, MBBS (Hons), FRACGP, with over 40 years of clinical experience.

3

Transparent pricing with no hidden fees. Complex autoimmune and inflammatory condition treatments range from $25,000 to $50,000 USD, with a clear breakdown provided during your no-obligation consultation.

4

Chiang Mai offers a relaxed recovery environment with access to fresh, wholesome food options that support digestive healing. The warm climate and low-stress setting complement the treatment protocol.

5

Structured follow-up at 1, 3, 6, and 12 months via secure video consultation with inflammatory marker tracking (CRP, faecal calprotectin) ensures your progress is monitored objectively long after you return home.

Can Stem Cell Therapy Help Achieve Remission in Crohn's Disease?

Many Crohn's disease patients struggle to achieve and maintain remission despite aggressive medical therapy including immunomodulators and biologic agents. Mesenchymal stem cells have demonstrated potent anti-inflammatory and tissue-reparative properties in clinical trials for inflammatory bowel disease, with European regulatory approval already granted for MSC-based treatment of perianal fistulae. Systemic MSC therapy may help modulate the dysregulated mucosal immune response driving chronic intestinal inflammation. At Boston Health Longevity, patients with refractory Crohn's disease are carefully assessed to determine whether regenerative therapy may support disease control.

Stem Cell Therapy for Crohn's Fistulae and Strictures

Perianal fistulae and intestinal strictures are among the most debilitating complications of Crohn's disease, often requiring repeated surgical interventions with variable success rates. Published clinical research has shown that locally administered mesenchymal stem cells can promote fistula healing in a significant proportion of patients. The tissue-reparative and anti-inflammatory properties of MSCs may also help address the fibrotic processes underlying stricture formation. Treatment protocols at Boston Health Longevity are tailored to each patient's specific disease pattern and complication profile.

Living with Crohn's Disease: Why Patients Seek Treatment in Thailand

Patients with Crohn's disease who have exhausted conventional treatment options often feel they have nowhere left to turn. The cycle of flares, hospitalisations, medication changes, and potential surgical interventions takes a profound toll on quality of life. Thailand offers a regulated environment where advanced regenerative therapies are accessible to international patients. Boston Health Longevity in Chiang Mai provides a structured treatment programme with comprehensive gastroenterological assessment, transparent pricing, and long-term follow-up to track disease activity and treatment response.

Treatment Comparison

Alternatives to surgery for Crohn's disease

Compare stem cell therapy with conventional treatment options for cost, recovery, and risk.

Factor Stem Cell Therapy Conventional / Surgery
Typical Cost (Thailand) $25,000 - $50,000 $15,000 - $40,000 (bowel resection)
Recovery Time Minimal downtime (varies by protocol) 4-8 weeks post-surgical recovery
Invasiveness Minimally invasive intravenous infusion Major abdominal surgery / ongoing biologics
Hospital Stay Varies by protocol 5-10 days inpatient (surgery) or ongoing infusions
Risk Level Low (cell-based, minimal side effects) Moderate-High (surgical complications, biologic side effects)
Return to Normal Activity Varies by protocol 4-8 weeks (surgery) or ongoing treatment burden

Treatment at Boston Health Longevity

$25,000 - $50,000

USD equivalent, personalised to your case

vs Home Country

$15,000 - $40,000 (bowel resection)

Internationally competitive pricing, same clinical standard

Costs are approximate. You receive a detailed, itemised quote after your initial assessment. Full pricing guide.

Considering treatment for crohn's disease?

Our clinical team at Boston Health Longevity provides no-obligation assessments for crohn's disease. Honest advice even if therapy isn't right for you. Most patients receive a response within 24 hours.

Apply for Consultation

Trusted by international patients from 11+ countries worldwide

Your Journey

What to expect

1

Comprehensive remote consultation with review of gastroenterology records, endoscopy, and imaging

2

Arrive in Chiang Mai, accommodation and logistics support provided

3

Day 1: Clinical assessment, blood work, inflammatory markers, and nutritional evaluation

4

Day 2: Stem cell preparation and administration via intravenous infusion

5

Day 3-5: Monitoring, dietary guidance, and discharge with comprehensive care plan

6

Structured remote follow-up at 1, 3, 6, and 12 months with inflammatory marker tracking

Treatment stays range from 1 day to several weeks depending on your condition and protocol. Read the International Patient Guide →

Frequently Asked Questions

Can stem cell therapy cure Crohn's disease?
No. Crohn's disease is a chronic condition and stem cell therapy is not a cure. It is an emerging approach that may help modulate the immune response and support intestinal healing. Clinical research has shown promising results, and we provide evidence-based counselling about realistic expectations.
What evidence supports stem cell therapy for IBD?
There is a growing body of clinical research supporting MSC therapy for inflammatory bowel disease. Notably, an MSC-based therapy has received European regulatory approval for complex perianal fistulae in Crohn's disease. Research continues into systemic MSC administration for broader Crohn's disease management.
Will I need to modify my current IBD medications?
Medication adjustments are assessed individually based on your current regimen. Some immunosuppressive medications may require temporary modification. All changes are carefully coordinated with your gastroenterologist to ensure safe management and continuity of care.
How is this different from surgery for Crohn's?
Surgery for Crohn's disease (bowel resection, strictureplasty) addresses structural complications but does not treat the underlying immune dysregulation. Stem cell therapy aims to modulate the immune response itself, potentially reducing inflammation and supporting tissue healing without surgical intervention.
Next Steps

Ready to explore crohn's disease treatment?

Our clinical team provides honest, no-obligation assessments. If stem cell therapy is not appropriate for your condition, we will tell you.

Most patients receive their initial assessment within 24 hours.

1

Submit Your Crohn's Disease Case

Share your crohn's disease medical history, imaging, and any previous treatment records for review.

2

Crohn's Disease Assessment

Our clinical team reviews your crohn's disease case and provides an honest recommendation on suitability.

3

Your Crohn's Disease Treatment Plan

Receive a personalised crohn's disease treatment plan with transparent pricing and expected outcomes.

Related Conditions

Other conditions we treat

Medical Disclaimer

The information on this page is for educational purposes only and does not constitute medical advice. Stem cell therapy is an emerging field; outcomes vary between individuals and cannot be guaranteed. No claims of cure or specific results are made. Always consult with a qualified healthcare provider before making treatment decisions. Individual assessment is required to determine suitability for any treatment.

Take the first step

Request a no-obligation assessment for crohn's disease treatment at Boston Health Longevity in Chiang Mai.

52

Conditions Treated

11

Countries Served

GMP

Certified Supply

Apply for Consultation

Every case personally reviewed by our clinical team within 24 hours

Apply for Consultation